Lymphoma – relapsed or refractory mediastinal B-Cell lymphoma

The PBS subsidises pembrolizumab for patients with relapsed or refractory mediastinal B-Cell lymphoma.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with pembrolizumab under the National Health Act 1953, section 100 – Efficient funding of chemotherapy for patients with relapsed or refractory mediastinal B-Cell lymphoma.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing pembrolizumab.

Section 100 EFC arrangements

These items are only PBS subsidised for day admitted patients, non-admitted patients, or patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital (IV trastuzumab only).

These items are not PBS subsidised for public hospital in-patients.

Authority applications

Apply for initial treatment

For initial authority approval to prescribe PBS subsidised pembrolizumab for the treatment of relapsed or refractory mediastinal B-Cell lymphoma apply in writing and either:

All applications must include the completed:

Apply for initial grandfather treatment

For patients who received non-PBS subsidised pembrolizumab treatment before 1 September 2020 for relapsed or refractory mediastinal B-Cell lymphoma, apply for initial grandfather authority approval in writing and either:

All applications must include the completed:

Continuing treatment

For authority applications to prescribe continuing PBS subsidised pembrolizumab to treat relapsed or refractory mediastinal B-Cell lymphoma apply either:

Further information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 18 September 2020